$AVNR..Will report out topline Ph.2 data for AVP-923 for the treatment of agitation in Alzheimer's late Sep/early Oct. Then they have PDUFA date on Nov 26th for AVP-825 for the treatment of Acute Migraine.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.